ESC 365 - Elegibility for Sacubitril/Valsartan in italian clinical practice: insights from the OPTIMA-HF registry

ESC Professional Premium Access

Elegibility for Sacubitril/Valsartan in italian clinical practice: insights from the OPTIMA-HF registry

Session: Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure

Topic: Pharmacotherapy

Speaker: Mrs S. Paolillo (Naples, IT)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mrs Stefania Paolillo

University of Naples Federico II, Naples (Italy)

0 follower

7 more presentations in this session

Guideline-directed medical therapy patterns in heart failure with reduced ejection fraction: the OPTIMA-HF registry

Speaker: Doctor S. Paolillo (Naples, IT)

Quality of life in patients with heart failure and improved ejection fraction: one-year follow-up with ARNI and SGLT2i

Speaker: Professor S. Tadic (Novi Sad, RS)

Real world evidence of Sacubitril/Valsartan in octogenarian patients with heart failure. Results From the PARACHUTE-HF Study

Speaker: Doctor N. Okuda (Kawagoe, JP)

Estimated plasma volume in heart failure with reduced ejection fraction: ACE inhibitors versus angiotensin receptor/neprilysin inhibitor in follow up

Speaker: Doctor S. Varga (Sisak, HR)

Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i

Speaker: Mrs O. Obertynska (Vinnitsa, UA)

Access the full session

Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure

Speakers: Mrs S. Paolillo, Doctor S. Paolillo, Professor S. Tadic, Doctor N. Okuda, Doctor S. Varga...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources